Palonosetron Hydrochloride (BioDeep_00000739137)
代谢物信息卡片
Palonosetron Hydrochloride
化学式: C19H25ClN2O (332.1655)
中文名称: 盐酸帕洛诺司琼, 盐酸派洛诺司琼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5.Cl
InChI: /m1./s1
描述信息
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent
D005765 - Gastrointestinal Agents > D000932 - Antiemetics
D002491 - Central Nervous System Agents
Palonosetron hydrochloride is a 5-HT3 antagonist that inhibits chemotherapy-induced nausea and vomiting (CINV).
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:85157
- KEGGdrug: D05343
- PubChem: 6918303
- ChEMBL: CHEMBL1720
- MeSH: Palonosetron
- CAS: 135729-62-3
- CAS: 135755-51-0
- medchemexpress: HY-A0021
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Ami Yoshida, Yoichi Murai, Yoshito Zamami, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Masayuki Chuma, Yuki Izawa-Ishizawa, Keisuke Ishizawa. Effects of 5-HT₃ receptor antagonists on cisplatin-induced kidney injury.
Clinical and translational science.
2021 09; 14(5):1906-1916. doi:
10.1111/cts.13045. [PMID: 33982438] - Junichi Hara, Yoshiyuki Kosaka, Katsuyoshi Koh, Kimikazu Matsumoto, Tadashi Kumamoto, Hiroyuki Fujisaki, Yuji Ishida, Ryoko Suzuki, Shinji Mochizuki, Hiroaki Goto, Yuki Yuza, Yuhki Koga. Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients.
Japanese journal of clinical oncology.
2021 Aug; 51(8):1204-1211. doi:
10.1093/jjco/hyab079. [PMID: 34021341] - R De Luca, C Volpe, O Mistretta, R Paci, G Ferrera, V Caputo, G Rosati, G Cicero. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
European review for medical and pharmacological sciences.
2021 08; 25(16):5310-5317. doi:
10.26355/eurrev_202108_26552. [PMID: 34486707] - Rui Chen, Hongyun Wang, Wen Zhong, Salvatore Chessari, Corinna Lanzarotti, Alberto Bernareggi, Pei Hu. Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 May; 160(?):105752. doi:
10.1016/j.ejps.2021.105752. [PMID: 33581259] - Tetsunari Hase, Masayuki Miyazaki, Kazuya Ichikawa, Naoyuki Yogo, Naoya Ozawa, Takahiro Hatta, Masahiko Ando, Mitsuo Sato, Masashi Kondo, Kiyofumi Yamada, Yoshinori Hasegawa. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
International journal of clinical oncology.
2020 Nov; 25(11):1928-1935. doi:
10.1007/s10147-020-01755-1. [PMID: 32740717] - Ziyi Yang, Lu Liu, Lili Su, Xueqing Wu, Yicheng Wang, Lei Liu, Xia Lin. Design of a zero-order sustained release PLGA microspheres for palonosetron hydrochloride with high encapsulation efficiency.
International journal of pharmaceutics.
2020 Feb; 575(?):119006. doi:
10.1016/j.ijpharm.2019.119006. [PMID: 31899319] - Sally Baron-Hay, Matti Aapro, Alberto Bernareggi, Lee Schwartzberg. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
2019 Apr; 27(4):1309-1317. doi:
10.1007/s00520-019-4640-8. [PMID: 30685793] - James Gilmore, Alberto Bernareggi. Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Journal of clinical pharmacology.
2019 04; 59(4):472-487. doi:
10.1002/jcph.1338. [PMID: 30412271] - Akihiko Osaki, Kenichi Inoue, Hiroshi Sakai, Kazuhiko Yamada, Koichi Minato, Fumiyoshi Ohyanagi, Yutaka Tokuda, Norihiko Ikeda, Hiroshi Kagamu, Kaoru Kubota, Tomohide Tamura, Toshiaki Saeki. A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy.
Japanese journal of clinical oncology.
2019 Feb; 49(2):121-129. doi:
10.1093/jjco/hyy161. [PMID: 30576544] - Naohisa Yoshida, Tetsuya Taguchi, Masayoshi Nakanishi, Ken Inoue, Tetsuya Okayama, Takeshi Ishikawa, Eigo Otsuji, Koichi Takayama, Haruo Kuroboshi, Motohiro Kanazawa, Yoshito Itoh. Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens.
BMC pharmacology & toxicology.
2019 Jan; 20(1):6. doi:
10.1186/s40360-018-0278-2. [PMID: 30642399] - Yukari Tsubata, Mika Nakao, Yoshihiro Amano, Takamasa Hotta, Megumi Hamaguchi, Tamio Okimoto, Kiyotaka Miura, Shunichi Hamaguchi, Takashige Kuraki, Masayuki Itakura, Takeshi Isobe. Translational and Randomized Study of 5-HT3 Receptor Antagonists for Evaluation of Chemotherapy-induced Nausea and Vomiting Related Biomarkers.
The journal of medical investigation : JMI.
2019; 66(3.4):269-274. doi:
10.2152/jmi.66.269. [PMID: 31656287] - Sheila A Doggrell. Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?.
Expert opinion on pharmacotherapy.
2017 Jul; 18(10):1019-1026. doi:
10.1080/14656566.2017.1342809. [PMID: 28612633] - Ihsan Ullah, Fazal Subhan, Zengbing Lu, Sze Wa Chan, John A Rudd. Action of Bacopa monnieri to antagonize cisplatin-induced emesis in Suncus murinus (house musk shrew).
Journal of pharmacological sciences.
2017 Apr; 133(4):232-239. doi:
10.1016/j.jphs.2017.03.001. [PMID: 28363413] - Mingzhen Xu, Yang Ni, Shihong Li, Juan Du, Huqun Li, Ying Zhou, Weiyong Li, Hui Chen. Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Aug; 1027(?):187-93. doi:
10.1016/j.jchromb.2016.05.051. [PMID: 27294531] - Qi Shi, Wen Li, Hongjia Li, Qiqi Le, Shanshan Liu, Shaoqi Zong, Leizhen Zheng, Fenggang Hou. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Oncotarget.
2016 Apr; 7(17):24402-14. doi:
10.18632/oncotarget.8255. [PMID: 27015550] - Cüneyt Türkeş, Hakan Söyüt, Şükrü Beydemir. In vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum.
Environmental toxicology and pharmacology.
2016 Mar; 42(?):252-7. doi:
10.1016/j.etap.2015.11.024. [PMID: 26915059] - Hiroshi Kitamura, Atsushi Takahashi, Hiroshi Hotta, Ryuichi Kato, Yasuharu Kunishima, Fumiyasu Takei, Hiroki Horita, Naoya Masumori. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
International journal of urology : official journal of the Japanese Urological Association.
2015 Oct; 22(10):911-4. doi:
10.1111/iju.12842. [PMID: 26087891] - Hironori Nakamura, Haruko Yokoyama, Risa Takayanagi, Koichi Yoshimoto, Akihiro Nakajima, Kiyoshi Okuyama, Osamu Iwase, Yasuhiko Yamada. Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
European journal of drug metabolism and pharmacokinetics.
2015 Mar; 40(1):39-44. doi:
10.1007/s13318-014-0175-z. [PMID: 24470169] - Nissar A Darmani, Weixia Zhong, Seetha Chebolu, Mariam Vaezi, Tursun Alkam. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
European journal of pharmacology.
2014 Jan; 722(?):2-12. doi:
10.1016/j.ejphar.2013.08.052. [PMID: 24513517] - Tulla Spinelli, Selma Calcagnile, Claudio Giuliano, Giorgia Rossi, Corinna Lanzarotti, Stuart Mair, Lloyd Stevens, Ian Nisbet. Netupitant PET imaging and ADME studies in humans.
Journal of clinical pharmacology.
2014 Jan; 54(1):97-108. doi:
10.1002/jcph.198. [PMID: 24122871] - Belen Sadaba, Anabel del Barrio, Miguel Angel Campanero, Jose Ramon Azanza, Almudena Gomez-Guiu, Jose Maria Lopez-Picazo, Salvador Martin Algarra, Francisco Guillén Grimá, Maria Blanco Prieto, Jose Luis Perez-Gracia, Alfonso Gurpide. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
PloS one.
2014; 9(2):e89747. doi:
10.1371/journal.pone.0089747. [PMID: 24587006] - Pengfei Li, Ping Ma, Yan Wang, Weihang Tong, Jing Wang, Cheng Wu, Lihong Liu. Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 May; 895-896(?):10-6. doi:
10.1016/j.jchromb.2012.03.001. [PMID: 22465199] - U Dogan, G Yavas, M Tekinalp, C Yavas, O Y Ata, K Ozdemir. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
European review for medical and pharmacological sciences.
2012 Apr; 16(4):462-8. doi:
NULL. [PMID: 22696873] - Shuyan Yang, Feng Qin, Dan Wang, Ning Li, Famei Li, Zhili Xiong. Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2012 Jan; 57(?):13-8. doi:
10.1016/j.jpba.2011.08.038. [PMID: 21937184] - Synia Haub, Yvonne Ritze, Inga Ladel, Karolin Saum, Astrid Hubert, Astrid Spruss, Christian Trautwein, Stephan C Bischoff. Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice.
The Journal of pharmacology and experimental therapeutics.
2011 Dec; 339(3):790-8. doi:
10.1124/jpet.111.181834. [PMID: 21903748] - Yuanyuan Wang, Yongqing Wang, Peipei Zhang, Zhihong Lu, Ying Gu, Ning Ou. Determination of palonosetron in human urine by LC-MS/MS.
Bioanalysis.
2011 Jun; 3(12):1337-42. doi:
10.4155/bio.11.110. [PMID: 21679028] - Mitsue Saito, Kenjiro Aogi, Ikuo Sekine, Hirohisa Yoshizawa, Yasuhiro Yanagita, Hiroshi Sakai, Kenichi Inoue, Chiyoe Kitagawa, Takashi Ogura, Shoichi Mitsuhashi. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
The Lancet. Oncology.
2009 Feb; 10(2):115-24. doi:
10.1016/s1470-2045(08)70313-9. [PMID: 19135415] - Li Ding, Yan Chen, Lin Yang, Aidong Wen. Determination of palonosetron in human plasma by liquid chromatography-electrospray ionization-mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
2007 Jun; 44(2):575-80. doi:
10.1016/j.jpba.2006.10.019. [PMID: 17127028] - Ajit Shah, Timothy DeGroot, Glen Apseloff. Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects.
Journal of clinical pharmacology.
2006 Oct; 46(10):1139-45. doi:
10.1177/0091270006291625. [PMID: 16988202] - Thomas L Hunt, Susan C Gallagher, Michael T Cullen, Ajit K Shah. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects.
Journal of clinical pharmacology.
2005 May; 45(5):589-96. doi:
10.1177/0091270005275061. [PMID: 15831783] - Ajit K Shah, Thomas L Hunt, Susan C Gallagher, Michael T Cullen. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Current medical research and opinion.
2005 Apr; 21(4):595-601. doi:
10.1185/030079905x40481. [PMID: 15899109] - Randall Stoltz, Simona Parisi, Ajit Shah, Alberto Macciocchi. Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers.
Biopharmaceutics & drug disposition.
2004 Nov; 25(8):329-37. doi:
10.1002/bdd.410. [PMID: 15378559] - Randall Stoltz, Jong-Chol Cyong, Ajit Shah, Simona Parisi. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects.
Journal of clinical pharmacology.
2004 May; 44(5):520-31. doi:
10.1177/0091270004264641. [PMID: 15102873] - P Eisenberg, F R MacKintosh, P Ritch, P A Cornett, A Macciocchi. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Annals of oncology : official journal of the European Society for Medical Oncology.
2004 Feb; 15(2):330-7. doi:
10.1093/annonc/mdh047. [PMID: 14760130] - M Asif A Siddiqui, Lesley J Scott. Palonosetron.
Drugs.
2004; 64(10):1125-32; discussion 1133. doi:
10.2165/00003495-200464100-00006. [PMID: 15139789] - Peter Eisenberg, Jazmin Figueroa-Vadillo, Rosalio Zamora, Veena Charu, Julio Hajdenberg, Alan Cartmell, Alberto Macciocchi, Steven Grunberg. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Cancer.
2003 Dec; 98(11):2473-82. doi:
10.1002/cncr.11817. [PMID: 14635083] - Steven M Grunberg, James M Koeller. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
Expert opinion on pharmacotherapy.
2003 Dec; 4(12):2297-303. doi:
10.1517/14656566.4.12.2297. [PMID: 14640928] - E H Wong, R Clark, E Leung, D Loury, D W Bonhaus, L Jakeman, H Parnes, R L Whiting, R M Eglen. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
British journal of pharmacology.
1995 Feb; 114(4):851-9. doi:
10.1111/j.1476-5381.1995.tb13282.x. [PMID: 7773546]
